MedTrace Logo

Aromatherapy Inhaler Use for HSCT Distress

NCT05302583 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-08-12

No results posted yet for this study

Summary

This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.

Conditions

  • Cancer Distress
  • Cancer Coping
  • Hematopoetic Stem Cell Transplant
  • Aromatherapy

Interventions

OTHER

Aromatherapy Stick

Participants receive aromatherapy inhaler education and an aromatherapy stick for self-administered inhalation during the early post-transplant inpatient period. Aromatherapy use occurs on the assigned Inhaler Use Day (targeted for Transplant Day +1, +2, or +3) and is documented using an inhaler use log. Total exposure is limited to a maximum of 2 hours.

OTHER

Standard of Care

Participants receive standard inpatient supportive care during the acute post-HCT period. No aromatherapy inhaler is provided.

Sponsors & Collaborators

Principal Investigators

  • Anna Oh, PhD, MPH, RN · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-16
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05302583 on ClinicalTrials.gov